Last reviewed · How we verify
NCT05983939
Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers
Phase 1 trial testing PIPE-791 in Multiple Sclerosis in 56 participants. Completed in 1 February 2024.
1 February 2024
Quick facts
| Lead sponsor | Contineum Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 56 |
| Start date | 26 June 2023 |
| Primary completion | 1 February 2024 |
| Estimated completion | 1 February 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PIPE-791 — full drug profile →
- Placebo
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
Sponsor
Contineum Therapeutics — full company profile →
Who can join
Adults 18 to 55, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD), Part 2 will be a Multiple Ascending Dose (MAD), and Part 3 will be a selected SAD cohort in a fed state. Safety will be assessed by periodic measurement of vital signs, physical examinations, electrocardiograms, blood laboratory analyses and occurrence of adverse events (AE).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis.
Poon M, Lorrain K, Broadhead A, Stebbins K, et al · · 2025 · PMID 40887574 · DOI 10.1186/s12931-025-03340-4
Verify or expand the search:
- PubMed search for NCT05983939
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PIPE-791
Trials testing the same drug.
- NCT06810245 — Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain · Phase 1 · completed
- NCT06683612 — PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF · Phase 1 · completed
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other Contineum Therapeutics trials
Trials by the same sponsor.
- NCT06810245 — Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain · Phase 1 · completed
- NCT06683612 — PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF · Phase 1 · completed
- NCT06083753 — Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis · Phase 2 · completed
- NCT04941781 — PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy · Phase 1 · completed
- NCT04725175 — Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05983939 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Contineum Therapeutics
- Last refreshed: 14 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05983939.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing